INACTIVATED POLIOMYELITIS VACCINE (DIPLOID CELL ORIGIN) - IPV 8 UNIT / 0.5 ML
INACTIVATED POLIOMYELITIS VACCINE (D.C.O.) TYPE 2 MEF1 : 8 UNIT / 0.5 ML INACTIVATED POLIOMYELITIS VACCINE (D.C.O.) TYPE 1 MAHONEY : 40 UNIT / 0.5 ML INACTIVATED POLIOMYELITIS VACCINE (D.C.O.) TYPE 3 SAUKETT : 32 UNIT / 0.5 ML · DIN 02231267 · SANOFI PASTEUR LIMITED
Health Canada status: CANCELLED POST MARKET
What is INACTIVATED POLIOMYELITIS VACCINE (DIPLOID CELL ORIGIN) - IPV?
INACTIVATED POLIOMYELITIS VACCINE (DIPLOID CELL ORIGIN) - IPV 8 UNIT / 0.5 ML contains INACTIVATED POLIOMYELITIS VACCINE (D.C.O.) TYPE 2 MEF1 : 8 UNIT / 0.5 ML INACTIVATED POLIOMYELITIS VACCINE (D.C.O.) TYPE 1 MAHONEY : 40 UNIT / 0.5 ML INACTIVATED POLIOMYELITIS VACCINE (D.C.O.) TYPE 3 SAUKETT : 32 UNIT / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02231267, held by SANOFI PASTEUR LIMITED, supplied as SOLUTION for SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 19-Sep-2014. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is INACTIVATED POLIOMYELITIS VACCINE (DIPLOID CELL ORIGIN) - IPV used for?
Inactivated Poliomyelitis Vaccine (Diploid Cell Origin) - IPV is indicated for active immunization against poliomyelitis caused by poliovirus types 1, 2 and 3 in infants, children and adults both for primary immunization and for boosters. It is recommended that all infants, unimmunized children and adolescents not previously immunized be vaccinated routinely against paralytic poliomyelitis.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02231267 |
|---|---|
| Brand name | INACTIVATED POLIOMYELITIS VACCINE (DIPLOID CELL ORIGIN) - IPV |
| Generic / active ingredient | INACTIVATED POLIOMYELITIS VACCINE (D.C.O.) TYPE 2 MEF1 : 8 UNIT / 0.5 ML INACTIVATED POLIOMYELITIS VACCINE (D.C.O.) TYPE 1 MAHONEY : 40 UNIT / 0.5 ML INACTIVATED POLIOMYELITIS VACCINE (D.C.O.) TYPE 3 SAUKETT : 32 UNIT / 0.5 ML |
| Manufacturer | SANOFI PASTEUR LIMITED |
| Strength | 8 UNIT / 0.5 ML |
| Dosage form | SOLUTION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | J07BF03 POLIOMYELITIS, TRIVALENT, INACTIVATED, WHOLE VIRUS |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 19-Sep-2014 |
| Original market date | 1998-11-17 00:00:00 |
How is it stored and handled?
Store at 2° to 8°C (35° to 46°F). DO NOT FREEZE. Discard product if exposed to freezing.
How is it supplied?
5 x 0.5 mL ampoules
What can be used instead?
Other Canadian products sharing ATC code J07BF03 POLIOMYELITIS, TRIVALENT, INACTIVATED, WHOLE VIRUS. 1 of 2 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| IMOVAX POLIO | 7 UNIT / 0.5 ML | SOLUTION | SANOFI PASTEUR LIMITED | MARKETED | DIN 01959042 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Request a quote for INACTIVATED POLIOMYELITIS VACCINE (DIPLOID CELL ORIGIN) - IPV
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.